新辅助化疗联合间隔肿瘤细胞减灭术治疗晚期卵巢癌的临床观察

目的:观察新辅助化疗与间隔肿瘤细胞减灭术联合治疗晚期卵巢癌的临床疗效。方法:选取我院收治的晚期卵巢癌患者88例,采取分层随机法分成两组,对照组采取间隔肿瘤细胞减灭术治疗,将全子宫、大网膜、双附件、肿瘤转移灶、阑尾切除,根据手术中的情况,切除腹主动脉旁、盆腔淋巴结及受累的脏器,观察组在对照组基础上采取新辅助化疗,行2-3次化疗后进行手术,采取TP方案进行新辅助化疗,150 mg/m~2紫杉醇,行静脉滴注,持续滴注3小时,每天1次;0.06卡铂、200 m L 0.9%氯化钠注射液,行静脉滴注,每天1-3次;每个疗程间隔3周。比较两组的临床治疗总有效率、腹水量、术中出血量、病灶大小、手术时间、住院时间。结果:观察组的治疗总有效率(75.00%)显著高于对照组(54.55%)(P0.05),腹水量、术中出血量均明显少于对照组,病灶显著小于对照组(P0.05),手术时间、住院时间均明显短于对照组(P0.05)。结论:新辅助化疗联合间隔肿瘤细胞减灭术治疗晚期卵巢癌患者的临床效果明显优于单用间隔肿瘤细胞减灭术。

Clinical Observation on the Efficacy of Neoadjuvant Chemotherapy Combined with Interval Cytoreductive Surgery in the Treatment of Advanced Ovarian Cancer

ABSTRACT Objective: To observe the clinical efficacy of cell neoadjuvant chemotherapy combined with interval cytoreductive surgery in the treatment of advanced ovarian cancer. Methods: 88 cases of patients with advanced ovarian cancer in our hospital were se- lected and randomly divided into two groups. The control group was given interval cytoreductive surgery treatment. The uterus, omen- tum, salping, tumor metastasis and appendix were removed, according to the situation, the para aortic, pelvic lymph node and tired organs were given resection. While the observation group was given new adjuvant chemotherapy on the basis of control group, with surgery fol- lowed by 2-3 times chemotherapy. And TP regimen neoadjuvant chemotherapy was used: 150 mg/m² paclitaxel, intravenous infusion, continuous infusion for 3 hours, once a day; 0.06 carboplatinum (CBP), 200 ml sodium chloride injection (0.9%), intravenous drip, 1-3 times a day; each treatment interval of 3 weeks. Then, the total effective rate, ascitic volume, intraoperative bleeding, lesion size, opera- tion time and hospital stay were respectively compared between two groups. Results: The total effective rate of observation group(75%) was significantly higher than that of the control group(54.55%)(P<0.05). The ascitic volume and intraoperative bleeding of observation group were obviously lower than those of the control group. The lesion was also less than that of the control group (P<0.05). The opera- tion time and the hospital stay were both shorter than those of the control group (P<0.05). Conclusion: The clinical efficacy of advanced ovarian cancer treated by cell neoadjuvant chemotherapy combined with interval cytoreductive surgery was significantly better than that of interval cytoreductive surgery alone.